2018
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer
Sundar R, Miranda S, Rodrigues D, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez D, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J. Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer 2018, 17: 280-284. PMID: 30042009, DOI: 10.1016/j.clcc.2018.05.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAtaxia Telangiectasia Mutated ProteinsBiomarkers, TumorColorectal NeoplasmsDNA RepairFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMaleMiddle AgedOxaliplatinPrognosisRetrospective StudiesSurvival RateYoung AdultConceptsATM lossColorectal cancerAssociated with superior overall survivalDNA repair targeting agentsMetastatic colorectal cancer patientsAtaxia telangiectasiaIrinotecan-based therapySuperior overall survivalOxaliplatin-based therapyOxaliplatin-based chemotherapyTreatment of colorectal cancerATM protein expressionClinical outcome dataNuclear staining intensityColorectal cancer patientsDrug Development UnitColorectal cancer samplesOverall survivalMutation statusH-scoreTargeted agentsClinical outcomesDNA repair signalingTumor samplesCancer patientsBiomarkers for Homologous Recombination Deficiency in Cancer
Hoppe M, Sundar R, Tan D, Jeyasekharan A. Biomarkers for Homologous Recombination Deficiency in Cancer. Journal Of The National Cancer Institute 2018, 110: 704-713. PMID: 29788099, DOI: 10.1093/jnci/djy085.Peer-Reviewed Original ResearchConceptsPoly-ADP-ribose polymeraseArray-based comparative genomic hybridizationSingle nucleotide polymorphismsHomologous recombination deficiencyPoly-ADP ribose polymerase inhibitorsComparative genomic hybridizationHomologous recombination genesNext-generation sequencingDNA repair pathwaysRecombination deficiencyClinical trialsGenomic hybridizationGermline BRCA1/2 mutation statusClinical development of PARP inhibitorsDefective DNA repairGenomic scarsResponse to platinum-based therapyHomologous recombinationDevelopment of PARP inhibitorsRecombinant genesNucleotide polymorphismsPlatinum-based therapyRibose polymeraseBRCA1/2 mutation statusDNA repair
2017
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Brown J, Sundar R, Lopez J. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. British Journal Of Cancer 2017, 118: 312-324. PMID: 29123260, PMCID: PMC5808021, DOI: 10.1038/bjc.2017.376.Peer-Reviewed Original ResearchConceptsImmunogenic cell deathDNA-damaging therapeuticsPromote immunogenic cell deathPhase I-III trialsDurable response rateDNA-damaging agentsAntitumour immune responseRegimens to patientsProperties of malignant cellsChoice of combinationsCell deathAntitumour immunitySequence of agentsNeoantigen productionTumor microenvironmentMalignant cellsNeoantigen repertoireInflammatory milieuPreclinical workImmune cellsCombination trialsDamaging agentsImmunological memoryMinimal toxicityHypothesis-driven trial